Related Experiment Video
Updated: May 16, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
A Santoro1, A Comandone, U Basso
1Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy. armando.santoro@cancercenter.humanitas.it
Summary
Sorafenib showed promise in advanced soft tissue sarcomas, particularly leiomyosarcoma. The drug was well-tolerated, suggesting potential for future histology-driven trials in sarcoma treatment.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Investigated the efficacy and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor.
- Focused on patients with advanced soft tissue sarcomas (STS) previously treated with anthracycline-based chemotherapy.
Purpose of the Study:
- To evaluate the activity and safety of sorafenib in advanced STS.
- To determine the progression-free survival (PFS) rate at 6 months as the primary endpoint.
Main Methods:
- An open-label, nonrandomized, multicenter phase II study.
- 101 patients with advanced STS received sorafenib 400 mg twice daily.
- Clinical outcomes and toxicity were assessed, stratified by histology, including leiomyosarcoma (L) and angiovascular sarcomas (A).
Main Results:
- In per-protocol analysis, 6-month PFS rates were 34.5% (all histologies), 38.4% (L), and 56.3% (A).
- Intention-to-treat analysis showed 6-month PFS rates of 27.1% (all), 35% (L), and 35.5% (A).
- Leiomyosarcoma demonstrated a statistically significant better PFS compared to other histologies (P = 0.033); treatment was well tolerated.
Conclusions:
- Sorafenib is a potential treatment option for patients with leiomyosarcoma.
- Further histology-driven clinical trials are warranted to confirm these findings.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...